FFS
VRTX icon

Founders Financial Securities’s Vertex Pharmaceuticals VRTX Stock Holding History

Founders Financial Securities’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.46M Sell
3,259
-405
-11% -$189K 0.08% 233
2025
Q4 		$1.66M Buy
3,664
+722
+25% +$311K 0.1% 196
2025
Q3 		$1.15M Buy
2,942
+1,787
+155% +$747K 0.08% 233
2025
Q2 		$514K Sell
1,155
-12
-1% -$5.53K 0.04% 340
2025
Q1 		$579K Buy
1,167
+20
+2% +$9.32K 0.05% 296
2024
Q4 		$462K Buy
1,147
+34
+3% +$15.8K 0.04% 319
2024
Q3 		$518K Sell
1,113
-146
-12% -$70.1K 0.05% 268
2024
Q2 		$590K Buy
1,259
+73
+6% +$31.7K 0.06% 258
2024
Q1 		$496K Buy
1,186
+184
+18% +$77.8K 0.05% 264
2023
Q4 		$408K Buy
1,002
+28
+3% +$10.3K 0.05% 272
2023
Q3 		$339K Buy
974
+73
+8% +$25.5K 0.04% 252
2023
Q2 		$317K Buy
901
+167
+23% +$56.3K 0.04% 257
2023
Q1 		$231K Hold
734
– – 0.03% 283
2022
Q4 		$212K Sell
734
-68
-8% -$20.7K 0.03% 300
2022
Q3 		$232K Sell
802
-57
-7% -$16.4K 0.04% 271
2022
Q2 		$242K Sell
859
-304
-26% -$81.4K 0.05% 222
2022
Q1 		$304K Buy
1,163
+112
+11% +$26.6K 0.05% 215
2021
Q4 		$231K Buy
+1,051
New +$204K 0.04% 235
2021
Q3 		– Sell
-997
Closed -$201K – 305
2021
Q2 		$201K Buy
+997
New +$209K 0.04% 284

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Founders Financial Securities's VRTX Position: Q1 2026 in Review

Founders Financial Securities reduced its Vertex Pharmaceuticals (VRTX) stake by 11% in Q1 2026, selling an estimated $189K and leaving 3,259 shares worth $1.46M. The position accounts for 0.08% of the portfolio, ranked #233.

Founders Financial Securities first reported a position in VRTX in Q2 2021 and has held it in 19 quarters since. The position peaked at $1.66M in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Founders Financial Securities held 3,259 shares of Vertex Pharmaceuticals worth $1.46M as of Q1 2026.
  • Founders Financial Securities sold 405 Vertex Pharmaceuticals shares in Q1 2026, an estimated $189K.
  • Vertex Pharmaceuticals made up 0.08% of Founders Financial Securities's portfolio in Q1 2026, its #233 holding.
  • Founders Financial Securities first reported a position in Vertex Pharmaceuticals in Q2 2021 and has held it in 19 quarters since.
  • Founders Financial Securities's Vertex Pharmaceuticals position peaked at $1.66M in Q4 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Founders Financial Securities's 13F filing for Q1 2026, filed 16 Apr 2026.